Australia's PharmAust rises on effective first patient dosing

Neurizon Therapeutics

14/02/2024 03:48

** Shares of PharmAust  PAA.AX  rise as much as 14.3% to
A$0.200, their highest level since Feb. 8
    ** Stock currently up 11.4%
    ** PAA headed for best day since Jan. 30, if gains hold 
    ** Pharmaceuticals co says first patient dosed in Open-Label
Extension (OLE) study at Calvary Health Care Bethlehem,
Melbourne
    ** Adds OLE study will investigate long-term safety,
tolerability, and efficacy of monepantel in patients with Motor
Neurone Disease/Amyotrophic Lateral Sclerosis
    ** Around 1.5 mln shares change hands vs 30-day average
volume of 914,724 shares
    ** Stock has risen 52.2% this year, as of last close

 (Reporting by Shivangi Lahiri in Bengaluru)
 ((shivangi.lahiri@thomsonreuters.com))